



Intercell's Japanese Encephalitis vaccine safe in Phase III trials

Vienna (Austria), January 12, 2006 – Intercell AG (VSE, "ICLL") announced today the achievement of an important milestone in the progress of its international, multi-center Phase III clinical trial program of its Japanese Encephalitis vaccine:

An independent Data and Safety Monitoring Board (DSMB), consisting of two European and one US expert from the field of Clinical Pharmacology and Vaccinology, has reviewed and evaluated the safety data from the first proportion of subjects vaccinated in the Phase III trial. After discussion of all safety data provided to the board members, the DSMB unanimously concluded that no safety concerns have been observed. From these preliminary results, the safety assessment is favorable which supports the ongoing rapid recruitment of approximately 5,000 subjects in the entire Phase III program.

Completion of recruitment for the pivotal safety and the pivotal immunogenicity trial is expected early this year.

Results of these Phase III trials are expected in mid 2006. First license applications will be made in the US, EU and Australia.

About Intercell's JE vaccine

Intercell's novel Japanese Encephalitis vaccine is a purified, inactivated vaccine for active immunization of adults against the Japanese Encephalitis virus and has successfully concluded Phase II clinical trials.

In the Phase II head-to-head comparison with JE-VAX®, Intercell's vaccine was shown to be:

- » Less reactogenic - both in frequency and intensity
- » More potent - higher antibody levels at all doses studied one month after the immunizations; this vaccine also showed high seroconversion rates one month after a single dose
- » More convenient - 2 doses versus 3 doses and liquid versus freeze-dried format
- » More persistent – higher persistence of antibodies two years after primary immunization

About Intercell

Intercell AG is a fast growing biotechnology company focusing on the design and development of novel vaccines for prevention and treatment of diseases with substantial unaddressed medical need. The Company's unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP manufacturing facilities. Intercell's technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis in Phase III, a vaccine for Hepatitis C in Phase II, a partnered Tuberculosis vaccine as well as a partnered *S. aureus* vaccine in Phase I and five products focused





on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL". For more information please visit: www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communication

Campus Vienna Biocenter 2

A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.